Henlius Licenses Phase 3 Innovative HER2 ADC from GeneQuantum
Recently, Shanghai Henlius Biotech, Inc. (2696.HK) has entered into a strategic collaboration with GeneQuantum Healthcare (Suzhou) Co., Ltd. ("GeneQuantum").
August 20, 2025
by Henlius
The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS
RemeGen Co., Ltd. announced that its phase 3 clinical trial (Study ID: RC48-C016) has reached its two primary endpoints of progression-free survival (PFS) and overall survival (OS).
May 12, 2025
by PR Newswire
Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis
Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis
December 13, 2024
by PRNewswire
Enhertu bags US priority review for HER2 gastric cancer
AstraZeneca’s Enhertu has scored a priority review from the US Food and Drug Administration (FDA) for the treatment of HER2-positive metastatic gastric cancer.
October 29, 2020
by pharmatimes
AZ, Daiichi grab blockbuster nod for breast cancer med Enhertu
For metastatic breast cancer patients who try and fail on multiple treatments, finding options to manage disease is a difficult proposition.
December 27, 2019
by fiercepharma
FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies
The U.S. Food and Drug Administration granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable ...
December 23, 2019
by worldpharmanews
SABCS: Addition of Tucatinib Ups Survival in HER2+ Metastatic Breast Cancer
Adding tucatinib to trastuzumab and capecitabine is associated with improved progression-free and overall survival among heavily pretreated patients with ...
December 12, 2019
by drugs
Drug Combo Slows Progression in Advanced Breast Cancer
Drug Combo Slows Progression in Advanced Breast Cancer.
June 25, 2019
by drugs
FDA Approves Roche's Kadcyla for HER2-Positive Early Breast Cancer
An adjuvant treatment for patients who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.
June 14, 2019
by contractpharma
Trastuzumab deruxtecan demonstrated clinically-meaningful response in patients with refractory HER2-positive metastatic breast cancer
Trastuzumab deruxtecan demonstrated clinically-meaningful response in patients with refractory HER2-positive metastatic breast cancer.
May 10, 2019
by worldpharmanews
Roche launches HER2 biomarker test for breast and gastric cancer
Roche has launched a new assay that can detect the HER2 biomarker in breast and gastric cancer in the UK.
May 9, 2019
by pharmatimes
Herceptin has been Excellent over the Two Decades
The subcutaneous injection: Herceptin Hylecta of the star drug Herceptin under Roche has recently been approved by FDA for...
April 10, 2019
by PharmaSources/Miling